News & Research
New studies, trials, regulatory changes and news about the compounds on Amino WRX. Items are collected automatically once a day and summarised by AI; they are not reviewed by an editor before they appear here. Read the original source before relying on anything.
Last updated 2026-10-17.
- FDA panel recommends peptides its own scientists rejected, CSPI warns
Nutrition Insight
CSPI has asked the FDA to reject July advisory votes favoring BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for compounding. It cites FDA staff findings that none of the seven peptides reviewed met bulk-compounding list standards.
- Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions
Holland & Knight
A law-firm alert says the 14 October 2026 OMB submission does not add any peptide to the 503A bulks list and would not cover research-use-only sales. July advisory votes remain non-binding, with six peptides recommended and DSIP not recommended.
- Trump administration advances plan for peptide drugs favored by RFK Jr.
NBC News
HHS has sent an unpublished interim access policy on compounding certain peptides to the White House. Sources say it would let pharmacies temporarily make unapproved peptides, including BPC-157, under enforcement discretion, which is not FDA approval.
- RegulatoryBPC-157BPC-157 (oral)TB-500AOD-9604IpamorelinMK-677 (oral)CJC-1295 No DACCJC-1295 with DAC2026-10-17WORLD ANTI-DOPING AGENCY PUTS PEPTIDES ON 2027 PROHIBITED LIST
Granfondo Daily News
Coverage of the 2027 WADA list says peptides are explicitly flagged under S0 at all times. BPC-157, TB-500, AOD-9604, ipamorelin, MK-677, and CJC-1295 remain named examples, and a prescription would not make them legal in sport.
- Regulatory2026-10-16Peptide plan heads to White House for review
POLITICO
POLITICO reports that the HHS peptide compounding plan has been filed for White House review. Industry expects enforcement discretion, but no public list yet says which peptides or conditions would be covered.
- RegulatorySLU-PP-332 (injectable)SLU-PP-332 (oral)SLU-PP-332 + 5-Amino-1MQ blend (oral)SLU-PP-332 + BAM-15 blend (oral)SLU-PP-332 + Orforglipron blend (oral)SLU-PP-9152026-10-162027 WADA Prohibited List: What Changes?
Fox Mandal
The 2027 WADA Prohibited List, effective 1 January 2027, names peptides as examples of non-approved substances and adds SLU-PP-332 and SLU-PP-915 as prohibited metabolic modulators. People covered by these anti-doping rules would not be allowed to use SLU-PP-332 after that date, while GLP-1 agonists such as semaglutide and tirzepatide remain permitted but monitored.
- Regulatory2026-10-15Peptides Interim Access Policy Advancing Despite US FDA Staff Concerns
Pink Sheet
White House reviewers are considering a temporary order that would allow compounding and dispensing of certain unapproved injectable peptides, despite concerns from career FDA staff. If issued, the order would be a short-term access step and not a finding that those peptides are safe or approved.
- Trump administration advances plan for peptide drugs favored by RFK Jr.
STAT News
Health officials have sent the White House a draft interim policy that would let pharmacies temporarily compound certain unapproved peptides, including BPC-157. The proposal is not an FDA approval, so compounded BPC-157 would remain unapproved while the review is pending.
- US FDA Peptide Compounding Policy: What Could Change?
Medindia
The public regulatory record shows an interim peptide-access filing was received on 14 October 2026 and is still pending, and it does not name covered peptides or lift existing limits. FDA has also said published safety information on compounded BPC-157 is too limited to judge its harms.
- TG SAFE warns against unapproved weight-loss drugs and peptides
Hyderabad Mail
Telangana’s drug authority warned against buying unapproved weight-loss drugs and experimental peptides, including orforglipron, tesamorelin, BPC-157, GHK-Cu and retatrutide, from unregulated online sellers. It said research-use labels do not make these products approved medicines and cited contamination, infection and other risks from injectables.
- Peptides: FDA urged to overrule advisory panel
Center for Science in the Public Interest
The Center for Science in the Public Interest asked the FDA to reject a pharmacy compounding advisory vote that recommended BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for the 503A bulks list. The group says the vote set aside FDA staff safety objections, and the request itself does not change current compounding rules.
- CagriSema: Results, Side Effects, and FDA Approval
Healthline
CagriSema, a combination of cagrilintide and semaglutide, remains unapproved, with an FDA decision expected in late 2026. The FDA has also said cagrilintide cannot legally be used in compounding.
- Regulatory2026-10-08US FDA Staff Push Back Against Trump Administration Interim Peptide Dispensing Order
Pink Sheet
FDA drug-center staff are reported to be unwilling to recommend a temporary order letting compounding pharmacies dispense certain unapproved peptides while permanent rules are drafted. They cited safety and the formal approval process, so compounded research peptides are not described as newly authorized.
- Regulatory2026-10-08The Trump administration seems like its leaning toward allowing unapproved peptides
The Verge
The administration is reported to be considering temporary sales of some unapproved peptides through compounding pharmacies. Which peptides would be covered, and when any order would start, has not been decided.
- Regulatory2026-10-12WADA publishes Prohibited List update for 2027
World Triathlon
The 2027 WADA Prohibited List, in force from 1 January 2027, adds examples under S0 non-approved substances. GLP-1 agonists, including semaglutide and tirzepatide, are left not prohibited while more data are collected.
- WHO guidelines on the integrated management of obesity in children
World Health Organization
WHO’s guideline on obesity in children under 10 recommends against medicines, including GLP-1 drugs, because safety and long-term effectiveness are not established. It puts structured lifestyle care first and treats drug treatment as unproven in that age group.
- Russian Football Union medical department: What will change in the WADA Prohibited List in 2027
Russian Football Union
A Russian Football Union medical briefing on the 2027 WADA Prohibited List says that from 1 January 2027 BPC-157 will be named as an S0 example and SLU-PP-332 and SLU-PP-915 will be named as metabolic-modulator examples. The briefing also says unapproved peptides that are not listed by name can still be prohibited under S0, S2, or S4.
- EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.
J Hepatol
European liver, diabetes, and obesity societies issued guidance on using semaglutide as MASH-targeted therapy. The GLP1-S page should treat MASH as a human-guidance use and cite this, rather than leaving liver benefit at a lower grade.